Join to View Full Profile
450 Brookline AveDana Farber Cancer InstituteBoston, MA 02215
Phone+1 617-632-3000
Dr. Hammerman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2008
Perelman School of Medicine at the University of PennsylvaniaClass of 2006
Certifications & Licensure
MA State Medical License 2008 - 2027
Clinical Trials
- Ponatinib for Squamous Cell Lung and Head and Neck Cancers Start of enrollment: 2013 Jan 01
- A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Start of enrollment: 2015 Jul 01
Publications & Presentations
PubMed
- 1 citationsExpressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.Jennifer L Cotton, Javier Estrada Diez, Vivek Sagar, Julie Chen, Michelle Piquet
Cancer Research. 2023-11-01 - 46 citationsSex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis.Katsuhiro Togami, Sun Sook Chung, Vikas Madan, Christopher A G Booth, Christopher M. Kenyon
Cancer Discovery. 2021-10-06 - 31 citationsInhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.Hui Qin Wang, Iain Mulford, Fiona Sharp, Jinsheng Liang, Sema Kurtulus
Cancer Research. 2021-06-01
Journal Articles
- Author Correction: EZH2 Inhibition Sensitizes BRG1 and EGFR Mutant Lung Tumours to TopoII InhibitorsPeter Hammerman, MD, Nature
- Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid TumorsJeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
- Exome and Genome Sequencing of Nasopharynx Cancer Identifies NF-κB Pathway Activating MutationsSimion I Chiosea, Peter S Hammerman, Jennifer R Grandis, Nicole G Chau, Nature
Press Mentions
Chutes & Ladders—J&J Science Chief Stoffels the Latest C-suite Leader to RetireOctober 15th, 2021- After 15 Years Helping Lead Early Cancer Research at Genentech, Malek Jumps Ship to Run Novartis' NIBR Oncology UnitOctober 14th, 2021
- Flagship Keeps Ex-FDA Commish Stephen Hahn Busy with Another CMO Gig; Daphne Koller Makes Key Hire at Insitro by Welcoming Google and Facebook VetSeptember 10th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
